Pradaxa (dabigatran) is a new generation blood thinner drug approved by the FDA in October 2010 to reduce the risk of stroke and blood clots in people with atrial fibrillation not caused by heart valve problems. Pradaxa is also prescribed to hip replacement and knee replacement patients to prevent post-surgical blood clots. Elevated risks of serious internal bleeding and death have been reported in Pradaxa users, as well as strokes and heart attacks upon sudden discontinuation of Pradaxa. Hare Wynn is currently investigating the following injuries related to Pradaxa usage:
• Irreversible Internal Bleeding
• Gastrointestinal Bleeding
• Intracranial (Brain) Hemorrhaging
• Kidney/Renal Bleeding and Damage
• Strokes / Transient Ischemic Attacks (TIA)
• Heart Attacks / Myocardial Infarction (MI)
If you or a loved one has taken Pradaxa and developed any of these injuries, you may qualify for this investigation. We are evaluating claims at this time and would like to hear from you.